[CME: Radioactive iodine therapy in thyroid cancer]

Area of Science:

• Oncology
• Nuclear Medicine

Background:

• Differentiated thyroid carcinomas (papillary and follicular) comprise 90% of thyroid tumors with good prognoses but risk recurrence.
• Radioactive iodine uptake is a key characteristic exploited for treatment.
• Postoperative radioactive iodine ablation aims to eradicate residual thyroid cells and aid in staging.

Observation:

• The study focuses on the efficacy of radioactive iodine ablation therapy in managing differentiated thyroid carcinomas.
• Thyroglobulin is identified as a crucial tumor marker for sensitive staging and monitoring.
• Radioactive iodine treatment is also employed for managing metastases, with papillary microcarcinoma being a notable exception.

Findings:

• Complete thyroid ablation significantly decreases the recurrence rate of differentiated thyroid carcinomas.
• Radioactive iodine therapy is effective for treating metastases.
• Papillary microcarcinoma typically requires only lobectomy.

Implications:

• Optimized radioactive iodine ablation protocols can improve patient outcomes by minimizing recurrence.
• The use of thyroglobulin as a tumor marker enhances postoperative surveillance and early detection of recurrence.
• Tailored treatment approaches, considering tumor subtype like papillary microcarcinoma, are essential for effective management.